Travere Therapeutics Inc (TVTX) fair value: what the stock is really worth
As of Oct 14, 2026: fair value of Travere Therapeutics Inc $9.18, price $53.27, upside -82.8%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 12, 2026.
How to read this chart
60‑month range $5.26 – $67.52 · fair‑value band $3.44 – $13.04 · the $53.27 price screens above the $9.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 12, 2026.
Follow Travere Therapeutics in your weekly email
Every Wednesday you see whether Travere Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Show moreShow less
The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.
The company is headquartered in San Diego, California.
Stock analysis
Travere Therapeutics Inc (TVTX) currently trades at $53.27, while our model-based Fair Value estimate is $9.18, 82.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $9.70 per share, and 0 of the 7 models we run sit above the $53.27 price.
Bear case: the Multiples group reads lowest at $2.93, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: $3.44 (bear) to $13.04 (bull), the price of $53.27 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Travere Therapeutics Inc reported revenue of $491M in FY2025 versus $132M in FY2021, a compound +38.9%/yr. Reported net income was −$25.5M in FY2025.
Key figures
Market cap $5.5B · P/S ratio 9.35 · EPS (TTM) $−0.7300 · Net margin −5.2% · Return on equity −236% · Return on assets (EBIT) −37.5% · Operating margin 2.3% · Revenue (TTM) $591M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).
What moves the price
The share trades about 21% below its 52-week high and 104% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −83%, TVTX screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.8300 to $11.01). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear$3.44Fair Value $9.18Bull$13.04
Price $53.27 · Upside -82.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+110.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.9%
Start year 2020 (pandemic). Over 10 years: +17.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−88.8% (2020) → −12.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+47.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+41.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +44.3% a year for the price and +38.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
AI conclusion: Extended patent coverage and remission data form the main strength yet thin evidence of a durable moat combined with negative net income and high leverage mark the central weakness.
Main risk: Dependence on a single key product could pressure revenues and margins if the leadership change disrupts commercial progress in the kidney indications.
Travere has secured extended patent coverage for FILSPARI in FSGS through 2037 while presenting new long-term data on sustained remission rates in its key kidney indications. The company also faces a leadership change with a new CEO starting in December. Will the added durability of its main product carry the business through the transition or highlight the limits of depending on one asset?
Compare Travere Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Below median
Fair Value upside−82.8% · Bottom 25%
Profitability
Return on assets−4.2% · Above median
Net margin (12 months)−7.4% · Below median
Operating margin (12 months)2.3% · Above median
Growth and dividend
Revenue growth48.2% · Top 25%
Balance sheet
Debt / equity2.72× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B48.14× · Priciest 25%
P/S (12 months)9.35× · Pricier than median
Price / free cash flow146.3× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Travere Therapeutics Inc (TVTX) overvalued or undervalued?
As of Oct 12, 2026, our model estimates a fair value of $9.18 versus a price of $53.27, about −83% upside (overvalued).
What is the fair value of TVTX?
Our model-based fair value for Travere Therapeutics Inc is $9.18 (as of Oct 12, 2026), built from audited fundamentals. The current price: $53.27.
What is the quality score of TVTX?
Travere Therapeutics Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Travere Therapeutics Inc (TVTX)?
Our model-based price target is the fair value of $9.18 (as of Oct 12, 2026) from 7 valuation models. Cautious scenario $3.44, optimistic scenario $13.04. It is a calculation from audited fundamentals, not an analyst target.
What is the Travere Therapeutics Inc stock forecast for 2026?
Our models put fair value at $9.18, about −83% upside versus a price of $53.27 (overvalued). Cautious scenario $3.44, optimistic scenario $13.04. The calculation is refreshed regularly with new filings.
What is the revenue of Travere Therapeutics Inc (TVTX)?
Travere Therapeutics Inc reported trailing-twelve-month revenue of about $591M (latest available figure, as of Oct 12, 2026).
What growth is priced into Travere Therapeutics Inc (TVTX)?
For today's price to be fair in a discounted-cash-flow model, Travere Therapeutics Inc would have to grow free cash flow by +47.7 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.9 % per year. As of Oct 12, 2026.
What discount rate (WACC) does the fair value of TVTX use?
Our models discount Travere Therapeutics Inc at 9.9 %: a base by market capitalisation (mid), damped by beta 1.06, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Travere Therapeutics Inc that is +47.7 % per year a year over ten years, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Travere Therapeutics Inc (TVTX) delivered so far?
Over the past 5 years revenue at Travere Therapeutics Inc grew +19.9 % a year. The price currently implies +47.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Travere Therapeutics Inc (TVTX) growing?
The median revenue growth in the sector is +5.5 % a year. That is the yardstick for the growth priced into Travere Therapeutics Inc (+47.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Travere Therapeutics Inc (TVTX)?
The free-cash-flow yield on the price is 0.76 %: that much free cash flow Travere Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Travere Therapeutics Inc (TVTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Travere Therapeutics Inc it is $9.18 per share (as of Oct 12, 2026), against a price of $53.27. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Travere Therapeutics Inc stock overvalued or undervalued in 2026?
As of Oct 12, 2026, TVTX trades above its calculated fair value: price $53.27, fair value $9.18, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TVTX?
No. The price is what the market pays today ($53.27); the fair value is what the company's own numbers justify ($9.18). For Travere Therapeutics Inc the two are $44.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Travere Therapeutics Inc worth?
The market values Travere Therapeutics Inc at about $5.5B (market capitalisation, as of Oct 12, 2026). Per share that is $53.27; our models calculate a fair value of $9.18 per share.
What do the bullish and bearish scenarios say about TVTX?
Our models span a range for Travere Therapeutics Inc: cautious scenario $3.44, base $9.18, optimistic $13.04 per share (as of Oct 12, 2026, price $53.27). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Travere Therapeutics Inc (TVTX)?
Balance-sheet figures for Travere Therapeutics Inc (as of Oct 12, 2026): return on equity −236.4%, debt of 2.72 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is TVTX from its 52-week high?
Travere Therapeutics Inc trades at $53.27, about 21% below its 52-week high of $67.52 and 104% above the low of $26.14 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of $9.18 is for.
Which stocks are comparable to Travere Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Travere Therapeutics Inc stock attractive at the current price?
The data as of Oct 12, 2026: price $53.27, calculated fair value $9.18 (−83%), Quality Score 38/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TVTX calculated?
We run Travere Therapeutics Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $9.18, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Travere Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Travere Therapeutics Inc (TVTX)?
The closing price on Oct 14, 2026 was $53.27. Our model-based fair value is $9.18, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Travere Therapeutics Inc right now?
The price sits above even our optimistic bull case ($13.04). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($3.44 to $13.04). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Travere Therapeutics Inc
How large is the market capitalisation of Travere Therapeutics Inc (TVTX)?
The market capitalisation of Travere Therapeutics Inc is $5.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Travere Therapeutics Inc (TVTX)?
The price-to-sales ratio of Travere Therapeutics Inc is 9.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Travere Therapeutics Inc (TVTX)?
Earnings per share at Travere Therapeutics Inc are $−0.7300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Travere Therapeutics Inc (TVTX)?
The net margin of Travere Therapeutics Inc is −5.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Travere Therapeutics Inc (TVTX)?
The return on equity (ROE) of Travere Therapeutics Inc is −236% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Travere Therapeutics Inc (TVTX)?
On an EBIT basis the return on assets of Travere Therapeutics Inc is −37.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Travere Therapeutics Inc (TVTX)?
The operating margin of Travere Therapeutics Inc is 2.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Travere Therapeutics Inc (TVTX)?
Revenue at Travere Therapeutics Inc is growing +48.2% versus a year earlier (3y avg +64.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Travere Therapeutics Inc (TVTX) carry?
The net debt of Travere Therapeutics Inc is $236M (fiscal year 2025, ≈ 6.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Travere Therapeutics Inc in the live analysis
One click puts Travere Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 12, 2026